netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Formulary Chapter 11: Eye - Full Chapter
11.06  Expand sub section  Treatment of glaucoma
11.06  Expand sub section  Beta-blockers
11.06  Expand sub section  Prostaglandin analogues
11.06  Expand sub section  Sympathomimetics
Brimonidine Tartrate (Alphagan®)
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice Eye drops

Apraclonidine (Iopidine®)
View adult BNF View SPC online View childrens BNF  Track Changes
Green 3
Eye drops

Restricted Item Ophthalmic consultant initiation only: Apraclonidine can be used long term for certain complex glaucoma cases where surgery is high risk. See also section 11.8.

unlicensed 1% - unlicensed use 
Brimonidine Tartrate 0.2% with Timolol 0.5% (Combigan®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Eye drops

Combination products are licensed for use when beta blocker monotherapy does not provide adequate treatment. Only use where patient has difficulty with compliance/administration.

11.06  Expand sub section  Carbonic anhydrase inhibitors and systemic drugs to top
11.06  Expand sub section  Miotics
 Non Formulary Items
Dipivefrine Hydrochloride  (Propine®)

View adult BNF View SPC online View childrens BNF Track Changes
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Track Changes
Display tracking information
click to search
Link to adult BNF
click to search
Link to children's BNF
click to search
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHS England

Traffic Light Status Information

Status Description


Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.   


These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.  


Not used   

Green 1

Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.   

Green 2

Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.  

Green 3

Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.  


Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.   


Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.